Cannabis Extract CT-921 Has a High Efficacy-Adverse Effect Profile in a Neuropathic Pain Model
Open Access
- 1 January 2020
- journal article
- research article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. 14, 3351-3361
Abstract
Background: Legalization of cannabis encourages the development of specific cultivars to treat disease such as neuropathic pain. Because of the large number of cultivars, it is necessary to prioritize extracts before proceeding to clinical trials. Purpose: To compare extracts of two unique cannabis cultivars (CT-921, CT-928) for treatment of neuropathic pain induced by constriction of sciatic nerve in mice and to illustrate the use of this animal model to set priority for future trials. Methods: Pain severity was measured by threshold force causing paw withdrawal. Dose-response relationships and time course were determined for intravenously injected extracts of cultivars and vehicle. The doses for allodynia relief were correlated with decreased respiratory rate, temperature and behavioral changes. Results: Effective analgesic dose for 50 and 95% (ED50An and ED95An) was 15, and 29 mg/kg for CT-921 and 0.9 and 4.7 for CT-928. At ED50An, for both extracts, the duration was 120 min. At ED95An, administration of CT-928 significantly decreased respiratory rate while CT-921 did not. CT-928 decreased temperature more than CT-921. CT-928 produced frantic hyperactivity not seen with CT-921. At equivalent analgesic doses, THC was much less in CT-921 than in CT-928 suggesting interactions with components other than THC influenced the analgesia. At equivalent analgesic doses, efficacy-to-adverse effect profile for CT-928 was worse than for CT-921. Conclusion: Both extracts relieved neuropathic pain; however, CT-921 had a better efficacy-to-adverse effect profile, a rational basis for prioritizing cultivars for future clinical evaluation.Keywords
This publication has 39 references indexed in Scilit:
- Does Cannabidiol Protect Against Adverse Psychological Effects of THC?Frontiers in Psychiatry, 2013
- Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-beingPsychological Medicine, 2011
- Antihyperalgesic effect of aCannabis sativaextract in a rat model of neuropathic pain: mechanisms involvedPhytotherapy Research, 2008
- Neuropathic painNeurology, 2008
- Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trialPain, 2007
- Studying sex and gender differences in pain and analgesia: A consensus reportPain, 2007
- Δ9-Tetrahydrocannbinol Accounts for the Antinociceptive, Hypothermic, and Cataleptic Effects of Marijuana in MiceThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Combination of Δ9-Tetrahydrocannabinol with Oxymorphone or PentobarbitalAnesthesiology, 1975
- Intravenous Δ9-TetrahydrocannabinolAnesthesiology, 1975
- Inhalation, parenteral and oral LD50 values of Δ9-tetrahydrocannabinol in Fischer ratsToxicology and Applied Pharmacology, 1974